OptimizeRx Surges on Strong Financial Results and Upgraded Price Target

OptimizeRx shares are trading higher after the company reported a year-over-year revenue increase of over 30% in Q2 and raised its fiscal year guidance. Additionally, Roth Capital raised its price target for the stock to $27 from $22, maintaining a Buy rating due to the company's strong performance and future growth potential.